We performed a genome-scale CRISPR/Cas9 screening in the CD19+ human ALL cell line Nalm6 to systematically identify genetic perturbations that regulate resistance to CAR T-cell therapy. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.